Armata Pharmaceuticals, Inc.: Clinical Trials

11 completed, 2 no longer available. 10 Phase 2, 3 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 10
Phase 1	3	Completed 3

Follow Armata Pharmaceuticals, Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection AP-PA02, Placebo - Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa	Phase 2	Completed	Armata Pharmaceuticals, Inc.	48	2023-01-10	2026-01-05
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus	Phase 1 / Phase 2	Completed	Armata Pharmaceuticals, Inc.	56	2022-04-26	2026-03-23
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis AP-PA02, Placebo - Cystic Fibrosis, Pseudomonas Aeruginosa	Phase 1 / Phase 2	Completed	Armata Pharmaceuticals, Inc.	29	2020-12-22	2024-01-31
A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects C16G2, Placebo - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	20	2017-07-07	2022-12-22
A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application C16G2 Strip, Placebo Strip - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	30	2017-02-09	2022-12-22
A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects C16G2 Varnish, Placebo Varnish - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	33	2017-01-27	2022-12-29
Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults AB-SA01 (10^8 PFU per phage), AB-SA01 (10^9 PFU per phage), Placebo (for Cohort 10^8) - Healthy Volunteers	Phase 1	Completed	Armata Pharmaceuticals, Inc.	12	2016-05-01	2016-08-31
Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects C16G2 Gel, Placebo - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	135	2015-11-01	2019-08-01
Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects C16G2, Placebo - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	64	2015-07-01	2019-08-01
Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses C16G2 - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	52	2014-10-01	2019-08-01
Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults C16G2 Rinse, Placebo, C16G2 Gel - Dental Caries	Phase 2	Completed	Armata Pharmaceuticals, Inc.	60	2014-02-01	2019-08-01
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic AB-PA01		No longer available	Armata Pharmaceuticals, Inc.			2019-05-29
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic AB-SA01		No longer available	Armata Pharmaceuticals, Inc.			2019-05-29

Conditions studied

Dental Caries (7)  ·  Pseudomonas Infections (2)  ·  Bacteremia (1)  ·  Cystic Fibrosis (1)  ·  Staphylococcal Infections (1)

Interventions

Antimicrobial Peptides (3)

Countries

United States (11)  ·  Australia (1)

Top investigators

John Pittaway, DMD (3)  ·  Adam D Marberger, DDS (1)  ·  Adam Marberger, DDS (1)  ·  Deborah Birx, MD (1)  ·  Jeffrey Livezey, MD (1)  ·  John F Pittaway, DMD (1)  ·  Mark Wolff, DDS, PhD (1)  ·  Mark Wolff, MD (1)  ·  Mina Pastagia, MD, MS (1)